SEARCH

SEARCH BY CITATION

In 1993, recombinant interferon beta-1b (Betaseron®, Berlex Laboratories) was approved by the Food and Drug Administration as a treatment for relapsing-remitting multiple sclerosis (MS). Betaseron® is the first therapeutic agent licensed for use with patients with MS in more than 20 years. Many patients and their families have expressed great interest in obtaining information about this agent. In response, MS centers throughout the United States have developed Betaseron® training programs. This article describes how rehabilitation nurses can educate patients and families about Betaseron®.